Collectively, these results suggest that reducing neutrophil and macrophage infiltration improves OS in patients with HCC, and that targeting CCL2/CCR2 and CXCL8/CXCR2 chemotaxis is feasible as a potential therapeutic strategy. Here, CXCR2 is linked to hepatocellular carcinoma.